Published in Cell Immunol on December 15, 2001
Hidden talents of natural killers: NK cells in innate and adaptive immunity. EMBO Rep (2009) 1.60
Following TRAIL's path in the immune system. Immunology (2009) 1.60
Tumor immunoediting and immunosculpting pathways to cancer progression. Semin Cancer Biol (2007) 1.55
TRAIL-R deficiency in mice enhances lymph node metastasis without affecting primary tumor development. J Clin Invest (2008) 1.45
Role of cancer microenvironment in metastasis: focus on colon cancer. Cancer Microenviron (2008) 1.37
Escape of HIV-1-infected dendritic cells from TRAIL-mediated NK cell cytotoxicity during NK-DC cross-talk--a pivotal role of HMGB1. PLoS Pathog (2010) 1.37
Metastatic Latency and Immune Evasion through Autocrine Inhibition of WNT. Cell (2016) 1.36
Tumor suppressor IRF-1 mediates retinoid and interferon anticancer signaling to death ligand TRAIL. EMBO J (2004) 1.29
Suppression of tumor formation in lymph nodes by L-selectin-mediated natural killer cell recruitment. J Exp Med (2005) 1.21
Cellular FLICE-inhibitory protein: an attractive therapeutic target? Expert Opin Ther Targets (2003) 1.21
Metastatic susceptibility locus, an 8p hot-spot for tumour progression disrupted in colorectal liver metastases: 13 candidate genes examined at the DNA, mRNA and protein level. BMC Cancer (2008) 1.03
Immune and hemorheological changes in chronic fatigue syndrome. J Transl Med (2010) 1.01
Adoptively transferred TRAIL+ T cells suppress GVHD and augment antitumor activity. J Clin Invest (2013) 0.96
Cancer stem cell immunology: key to understanding tumorigenesis and tumor immune escape? Front Immunol (2014) 0.93
Application of tissue-specific NK and NKT cell activity for tumor immunotherapy. J Autoimmun (2009) 0.92
Intratracheal administration of a nanoparticle-based therapy with the angiotensin II type 2 receptor gene attenuates lung cancer growth. Cancer Res (2012) 0.89
Metastasis suppressor function of tumor necrosis factor-related apoptosis-inducing ligand-R in mice: implications for TRAIL-based therapy in humans? Cancer Res (2008) 0.87
Influenza-induced expression of functional tumor necrosis factor-related apoptosis-inducing ligand on human peripheral blood mononuclear cells. Hum Immunol (2008) 0.87
Targeted expression of tumor necrosis factor-related apoptosis-inducing ligand TRAIL in skin protects mice against chemical carcinogenesis. Mol Cancer (2011) 0.84
Altered NK cell function in obese healthy humans. BMC Obes (2015) 0.81
Vectors for inhaled gene therapy in lung cancer. Application for nano oncology and safety of bio nanotechnology. Int J Mol Sci (2012) 0.80
Therapeutic applications of TRAIL receptor agonists in cancer and beyond. Pharmacol Ther (2015) 0.80
Lipopolysaccharide-induced expression of TRAIL promotes dendritic cell differentiation. Immunology (2010) 0.80
Cancer stem cells and immunoresistance: clinical implications and solutions. Transl Lung Cancer Res (2015) 0.79
Human NK cell subset functions are differentially affected by adipokines. PLoS One (2013) 0.78
Phenotype and functions of conventional and non-conventional NK cells. Curr Opin Immunol (2015) 0.78
The Biology of TRAIL and the Role of TRAIL-Based Therapeutics in Infectious Diseases. Antiinfect Agents Med Chem (2009) 0.77
Triptolide enhances the tumoricidal activity of TRAIL against renal cell carcinoma. FEBS J (2015) 0.75
Variants of Osteoprotegerin Lacking TRAIL Binding for Therapeutic Bone Remodeling in Osteolytic Malignancies. Mol Cancer Res (2015) 0.75
A Critical Role for CD200R Signaling in Limiting the Growth and Metastasis of CD200+ Melanoma. J Immunol (2016) 0.75
A -1573T>C SNP within the human TRAIL promoter determines TRAIL expression and HCC tumor progression. Cancer Med (2016) 0.75
Exploring the TRAILs less travelled: TRAIL in cancer biology and therapy. Nat Rev Cancer (2017) 0.75
Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol (1996) 6.79
A new I subregion (I-J) marked by a locus (Ia-4) controlling surface determinants on suppressor T lymphocytes. J Exp Med (1976) 6.11
T-cell regulation of antibody responses: demonstration of allotype-specific helper T cells and their specific removal by suppressor T cells. J Exp Med (1976) 5.11
Differential tumor surveillance by natural killer (NK) and NKT cells. J Exp Med (2000) 4.45
NKT cells: facts, functions and fallacies. Immunol Today (2000) 4.40
Endoscopic submucosal dissection for early gastric cancer: a large-scale feasibility study. Gut (2008) 4.07
Two distinct types of helper T cells involved in the secondary antibody response: independent and synergistic effects of Ia- and Ia+ helper T cells. J Exp Med (1978) 3.80
The tissue distribution of the B7-2 costimulator in mice: abundant expression on dendritic cells in situ and during maturation in vitro. J Exp Med (1994) 3.66
Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation (1994) 3.63
Natural killer cell depletion enhances virus synthesis and virus-induced hepatitis in vivo. J Immunol (1983) 3.58
B70 antigen is a second ligand for CTLA-4 and CD28. Nature (1993) 3.57
Metalloproteinase-mediated release of human Fas ligand. J Exp Med (1995) 3.53
Regulation of homocytotropic antibody formation in the rat. VI. Inhibitory effect of thymocytes on the homocytotropic antibody response. J Immunol (1971) 3.48
In vivo effects of anti-asialo GM1. I. Reduction of NK activity and enhancement of transplanted tumor growth in nude mice. J Immunol (1981) 3.34
Herschel detects a massive dust reservoir in supernova 1987A. Science (2011) 3.18
A glycolipid on the surface of mouse natural killer cells. Eur J Immunol (1980) 3.13
Critical contribution of liver natural killer T cells to a murine model of hepatitis. Proc Natl Acad Sci U S A (2000) 3.03
The role of antigen-specific T cell factors in the immune response. Adv Immunol (1979) 2.95
Delineation of DNA replication time zones by fluorescence in situ hybridization. EMBO J (1992) 2.94
Selective expression of H-2 (i-region) loci controlling determinants on helper and suppressor T lymphocytes. J Exp Med (1976) 2.94
Nrf2-deficient female mice develop lupus-like autoimmune nephritis. Kidney Int (2001) 2.90
Characterization of 21 newly established esophageal cancer cell lines. Cancer (1992) 2.87
Selective reduction of V alpha 14+ NK T cells associated with disease development in autoimmune-prone mice. J Immunol (1996) 2.83
Significance of myocytes with positive DNA in situ nick end-labeling (TUNEL) in hearts with dilated cardiomyopathy: not apoptosis but DNA repair. Circulation (1999) 2.80
Differential regulation of IkappaB kinase alpha and beta by two upstream kinases, NF-kappaB-inducing kinase and mitogen-activated protein kinase/ERK kinase kinase-1. Proc Natl Acad Sci U S A (1998) 2.76
Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nat Med (2001) 2.74
The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc Natl Acad Sci U S A (2001) 2.65
Two distinct pathways of specific killing revealed by perforin mutant cytotoxic T lymphocytes. Immunity (1994) 2.61
Regulation of homocytotropic antibody formation in the rat. 3. Effect of thymectomy and splenectomy. J Immunol (1971) 2.61
Increased levels of circulating intercellular adhesion molecule 1 in Kawasaki disease. Arthritis Rheum (1992) 2.56
Extracellular adenosine triphosphate and adenosine in cancer. Oncogene (2010) 2.53
Critical roles of TRAF2 and TRAF5 in tumor necrosis factor-induced NF-kappa B activation and protection from cell death. J Biol Chem (2001) 2.50
Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia (2009) 2.50
Perioperative blood transfusion promotes recurrence of hepatocellular carcinoma after hepatectomy. Surgery (1994) 2.45
Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis. Blood (2001) 2.45
"Apoptotic" myocytes in infarct area in rabbit hearts may be oncotic myocytes with DNA fragmentation: analysis by immunogold electron microscopy combined with In situ nick end-labeling. Circulation (1998) 2.43
Specific acceptance of cardiac allograft after treatment with antibodies to ICAM-1 and LFA-1. Science (1992) 2.43
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis. J Exp Med (2001) 2.37
Cloning, expression and chromosome locations of the human DNMT3 gene family. Gene (1999) 2.33
CD80 (B7) and CD86 (B70) provide similar costimulatory signals for T cell proliferation, cytokine production, and generation of CTL. J Immunol (1995) 2.28
Recurrence of hepatocellular carcinoma after surgery. Br J Surg (1996) 2.27
TRAF5, an activator of NF-kappaB and putative signal transducer for the lymphotoxin-beta receptor. J Biol Chem (1996) 2.23
Angiographic no-reflow phenomenon as a predictor of adverse long-term outcome in patients treated with percutaneous transluminal coronary angioplasty for first acute myocardial infarction. J Am Coll Cardiol (2000) 2.20
Hyperventilation as a specific test for diagnosis of coronary artery spasm. Am J Cardiol (1997) 2.16
Use of the human elongation factor 1 alpha promoter as a versatile and efficient expression system. Gene (1990) 2.14
B70/B7-2 is identical to CD86 and is the major functional ligand for CD28 expressed on human dendritic cells. J Exp Med (1994) 2.14
CD48 is a counter-receptor for mouse CD2 and is involved in T cell activation. J Exp Med (1992) 2.13
Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: A novel mechanism for the antitumor effects of type I IFNs. J Exp Med (1999) 2.13
Transforming growth factor beta induces IgA production and acts additively with interleukin 5 for IgA production. J Exp Med (1989) 2.12
Inactivating mutations in the 25-hydroxyvitamin D3 1alpha-hydroxylase gene in patients with pseudovitamin D-deficiency rickets. N Engl J Med (1998) 2.11
Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma. Proc Natl Acad Sci U S A (2007) 2.10
Activation of hepatic NKT cells and subsequent liver injury following administration of alpha-galactosylceramide. Eur J Immunol (2000) 2.09
CD4+CD8+ thymocytes are susceptible to DNA fragmentation induced by phorbol ester, calcium ionophore and anti-CD3 antibody. Eur J Immunol (1990) 2.08
Nitric oxide activity is deficient in spasm arteries of patients with coronary spastic angina. Circulation (1996) 2.06
Telomestatin, a novel telomerase inhibitor from Streptomyces anulatus. J Am Chem Soc (2001) 2.05
Ubiquitin-dependent degradation of IkappaBalpha is mediated by a ubiquitin ligase Skp1/Cul 1/F-box protein FWD1. Proc Natl Acad Sci U S A (1999) 2.04
Fas and its ligand in a general mechanism of T-cell-mediated cytotoxicity. Proc Natl Acad Sci U S A (1994) 2.04
Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure. Circulation (1993) 2.04
An unusual isopentenyl diphosphate isomerase found in the mevalonate pathway gene cluster from Streptomyces sp. strain CL190. Proc Natl Acad Sci U S A (2001) 2.00
Molecular cloning of cDNA encoding human DNA helicase Q1 which has homology to Escherichia coli Rec Q helicase and localization of the gene at chromosome 12p12. Nucleic Acids Res (1994) 2.00
NKT cells are phenotypically and functionally diverse. Eur J Immunol (1999) 1.97
A light-independent oscillatory gene mPer3 in mouse SCN and OVLT. EMBO J (1998) 1.92
Characterization of T antigen in cells infected with a temperature-sensitive mutant of simian virus 40. J Virol (1975) 1.91
Protective roles of mast cells against enterobacterial infection are mediated by Toll-like receptor 4. J Immunol (2001) 1.90
Soluble Fas (APO-1, CD95) and soluble Fas ligand in rheumatic diseases. Arthritis Rheum (1997) 1.90
A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation. Cancer Res (1996) 1.90
4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar efficacy. J Immunol (2001) 1.90
Molecular cloning and expression of megakaryocyte potentiating factor cDNA. J Biol Chem (1995) 1.88
Resistance of Fc receptor- deficient mice to fatal glomerulonephritis. J Clin Invest (1998) 1.88
Zinc is a potent inhibitor of the apoptotic protease, caspase-3. A novel target for zinc in the inhibition of apoptosis. J Biol Chem (1997) 1.88
Regulation of immunoglobulin and antibody production by allotype suppressor T cells in mice. Transplant Rev (1975) 1.86
Molecular cloning and expression of the murine interleukin-5 receptor. EMBO J (1990) 1.85
Differential regulation of Th1 and Th2 functions of NKT cells by CD28 and CD40 costimulatory pathways. J Immunol (2001) 1.85
Perforin is a major contributor to NK cell control of tumor metastasis. J Immunol (1999) 1.83